J&J, Protagonist reveal two Phase 3 wins for oral IL-23 drug that’s expected to be a blockbuster

Johnson & Johnson and Protagonist Therapeutics announced two Phase 3 successes for their oral IL-23 drug, showcasing the first results out of an expansive pivotal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

The prevalence of clustering of health behaviors and associated physical and mental health outcomes

Researchers conducted a systematic review of the literature investigating the associations between lifestyle, health behaviors, and health outcomes.

August 23, 2023

Note from the Editor-in-Chief

Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. Dear reader, Today, Industry Dive, the company

December 3, 2024

Slow Cannabis Sales Growth in Illinois in June

Illinois adult-use cannabis sales in June were down 3.1% sequentially to a $141.8 million, which was about the same on a per-day basis from the longer May.

July 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.